EPISODE · Sep 8, 2025 · 21 MIN
#30 EditForce (2): Unlocking RNA technology - EditForce’s Challenge and future
from Tech Startupの舞台裏 · host UTEC
Following the first half which was recorded in Japanese, the second half dives deeper into the uniqueness and potential of EditForce’s technology!The unique PPR platform and the mechanism behind EditForce’s RNA editingLead program EF210 and its approach to high unmet medical needsProductive discussions with FDA and PMDA and preparations for clinical trialsTransforming from a research-driven to a business-driven organization — cultural shifts and challengesPartnership opportunities and the vision for expanding the platformGuest: Takashi Ono, President and CEO of EditForceHost: Priyanka Soni, Senior Associate and Maiko Iinuma, HR at UTEC◆ Guest ProfileTakashi OnoMr. Ono began his career at Sosei Co., Ltd. (now Nxera Pharma Co., Ltd.) in 2002, serving as Manager and then Head of Business Development. In 2009, he joined ITOCHU Corporation as a Project Manager in the Development and Research Department, while concurrently serving as Head of Business Development at Solasia Pharma K.K. He joined EditForce Inc. as Director and COO in 2018, and has served in his current role since March 2019.◆ About EditForce Inc.EditForce Inc. is a biotechnology venture company engaged in drug discovery and seed/plant breeding based on nucleic acid (DNA/RNA) manipulation technologies. The company was founded in 2015 by KISCO Ltd. and Professor Takahiro Nakamura of Kyushu University (Associate Professor at the time, currently Professor).In addition to proprietary genome editing, EditForce provides the world’s first “transcriptome editing” tool, enabling RNA manipulation on a genome-wide scale. This pioneering platform is based on engineering technology for PPR (pentatricopeptide repeat) proteins, invented by Professor Nakamura.Originally studied in the context of plant immunity, PPR proteins are capable of recognizing nucleic acid sequences (DNA/RNA). By elucidating this mechanism, EditForce has developed novel genome design and programming tools using PPR proteins, aiming to apply them across pharmaceuticals, agriculture, and other industries.Official Website: https://www.editforce.co.jp/If you are interested in an investment from UTEC, please contact us via the form below.https://share.hsforms.com/1_WfJXAagSWmKnsxVxSalXQc3fla
What this episode covers
Following the first half which was recorded in Japanese, the second half dives deeper into the uniqueness and potential of EditForce’s technology!The unique PPR platform and the mechanism behind EditForce’s RNA editingLead program EF210 and its approach to high unmet medical needsProductive discussions with FDA and PMDA and preparations for clinical trialsTransforming from a research-driven to a business-driven organization — cultural shifts and challengesPartnership opportunities and the vision for expanding the platformGuest: Takashi Ono, President and CEO of EditForceHost: Priyanka Soni, Senior Associate and Maiko Iinuma, HR at UTEC◆ Guest ProfileTakashi OnoMr. Ono began his career at Sosei Co., Ltd. (now Nxera Pharma Co., Ltd.) in 2002, serving as Manager and then Head of Business Development. In 2009, he joined ITOCHU Corporation as a Project Manager in the Development and Research Department, while concurrently serving as Head of Business Development at Solasia Pharma K.K. He joined EditForce Inc. as Director and COO in 2018, and has served in his current role since March 2019.◆ About EditForce Inc.EditForce Inc. is a biotechnology venture company engaged in drug discovery and seed/plant breeding based on nucleic acid (DNA/RNA) manipulation technologies. The company was founded in 2015 by KISCO Ltd. and Professor Takahiro Nakamura of Kyushu University (Associate Professor at the time, currently Professor).In addition to proprietary genome editing, EditForce provides the world’s first “transcriptome editing” tool, enabling RNA manipulation on a genome-wide scale. This pioneering platform is based on engineering technology for PPR (pentatricopeptide repeat) proteins, invented by Professor Nakamura.Originally studied in the context of plant immunity, PPR proteins are capable of recognizing nucleic acid sequences (DNA/RNA). By elucidating this mechanism, EditForce has developed novel genome design and programming tools using PPR proteins, aiming to apply them across pharmaceuticals, agriculture, and other industries.Official Website: https://www.editforce.co.jp/If you are interested in an investment from UTEC, please contact us via the form below.https://share.hsforms.com/1_WfJXAagSWmKnsxVxSalXQc3fla
NOW PLAYING
#30 EditForce (2): Unlocking RNA technology - EditForce’s Challenge and future
No transcript for this episode yet
Similar Episodes
Feb 24, 2026 ·13m
Feb 17, 2026 ·9m
Feb 11, 2026 ·7m
Feb 3, 2026 ·7m
Jan 27, 2026 ·8m
Jan 20, 2026 ·7m